China Universal Asset Management Co. Ltd. Raises Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

China Universal Asset Management Co. Ltd. lifted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 14.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 10,360 shares of the company’s stock after acquiring an additional 1,275 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Enliven Therapeutics were worth $233,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of Enliven Therapeutics by 10.6% in the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock valued at $160,804,000 after purchasing an additional 601,611 shares during the last quarter. Lord Abbett & CO. LLC purchased a new position in Enliven Therapeutics during the 3rd quarter worth approximately $8,199,000. Janus Henderson Group PLC increased its position in Enliven Therapeutics by 43.0% during the third quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock worth $26,611,000 after buying an additional 313,019 shares during the period. Ally Bridge Group NY LLC purchased a new stake in Enliven Therapeutics in the third quarter valued at approximately $5,998,000. Finally, First Turn Management LLC boosted its holdings in shares of Enliven Therapeutics by 29.5% in the third quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock valued at $13,666,000 after acquiring an additional 121,849 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock opened at $21.86 on Monday. Enliven Therapeutics, Inc. has a one year low of $10.90 and a one year high of $30.03. The company has a market cap of $1.07 billion, a P/E ratio of -11.51 and a beta of 1.04. The firm has a fifty day moving average of $23.04 and a two-hundred day moving average of $24.27.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Robert W. Baird upped their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. BTIG Research began coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $38.25.

Insider Buying and Selling

In other news, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $21.59, for a total transaction of $70,167.50. Following the completion of the transaction, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at approximately $280,670. This represents a 20.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Anish Patel sold 21,700 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $24.18, for a total value of $524,706.00. The disclosure for this sale can be found here. Insiders sold 35,450 shares of company stock valued at $845,048 over the last ninety days. Corporate insiders own 29.20% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.